NASDAQ:DBTX Decibel Therapeutics (DBTX) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free DBTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.90▼$5.1150-Day Range$4.91▼$5.2352-Week Range$1.61▼$5.40Volume1.26 million shsAverage Volume122,002 shsMarket Capitalization$123.39 millionP/E RatioN/ADividend YieldN/APrice Target$5.25 Stock AnalysisStock Analysis Get Decibel Therapeutics alerts: Email Address Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. About Decibel Therapeutics Stock (NASDAQ:DBTX)Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. As of September 25, 2023, Decibel Therapeutics, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.Read More Ad Paradigm PressBitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. DBTX Stock News HeadlinesMarch 28, 2024 | cnet.comBest Noise-Canceling Headphones Under $100 for 2024March 5, 2024 | nytimes.comNoise-Induced Hearing Loss in Kids Is a Growing Problem. Here’s How to Protect Little Ears.April 19, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…February 14, 2024 | nytimes.comSound Machines Aren’t Just for Sleep. Here’s How to Use Brown Noise to Focus at Work.November 17, 2023 | nytimes.comThe Best Noise-Cancelling HeadphonesSeptember 15, 2023 | seekingalpha.comDecibel Therapeutics' CVR Appears Around Fair ValueSeptember 12, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DBTX, CPRI, CEQP, ESTEAugust 31, 2023 | benzinga.comMoore Kuehn Encourages CTG, KLR, ZYNE, and DBTX Investors to Contact Law FirmApril 19, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…August 13, 2023 | businesswire.comDECIBEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Decibel ...August 12, 2023 | msn.comHC Wainwright & Co. Downgrades Decibel Therapeutics (DBTX)August 11, 2023 | finance.yahoo.comBiotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More NewsAugust 11, 2023 | finanznachrichten.deDecibel Therapeutics, Inc.: Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate UpdateAugust 11, 2023 | finance.yahoo.comDecibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate UpdateAugust 11, 2023 | msn.comBaird downgrades Decibel to neutral to reflect Regeneron takeoverAugust 10, 2023 | msn.comBaird Downgrades Decibel Therapeutics (DBTX)August 10, 2023 | finance.yahoo.comDecibel Therapeutics, Inc. (NASDAQ:DBTX) surges 80%; private equity firms who own 41% shares profited along with institutionsAugust 9, 2023 | washingtonpost.comComplaints about airplane noise rise at Reagan National, DullesAugust 9, 2023 | msn.comRegeneron to acquire gene therapy developer Decibel for $4 per shareAugust 9, 2023 | msn.comDecibel Therapeutics (NASDAQ:DBTX) Skyrockets On Acquisition By RegeneronAugust 9, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Decibel Therapeutics, Inc. has obtained a Fair Price in its transaction with RegeneronAugust 9, 2023 | finance.yahoo.comRegeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss ProgramsJuly 21, 2023 | finance.yahoo.comDBTX - Decibel Therapeutics, Inc.June 22, 2023 | markets.businessinsider.comRobert W. Baird Reaffirms Their Buy Rating on Decibel Therapeutics (DBTX)June 6, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Decibel Therapeutics (DBTX)June 2, 2023 | finance.yahoo.comDecibel Therapeutics to Participate in the Upcoming Jefferies Healthcare ConferenceJune 1, 2023 | finance.yahoo.comDecibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual MeetingSee More Headlines Receive DBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Decibel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:DBTX CUSIPN/A CIK1656536 Webdecibeltx.com Phone617-370-8701FaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Target$5.25 High Stock Price Target$5.25 Low Stock Price Target$5.25 Potential Upside/Downside+6.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-84.03% Return on Assets-53.90% Debt Debt-to-Equity RatioN/A Current Ratio3.03 Quick Ratio3.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book1.50Miscellaneous Outstanding Shares25,130,000Free Float16,182,000Market Cap$123.39 million OptionableNot Optionable Beta-0.43 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Laurence E. Reid Ph.D. (Age 59)Pres & CEO Comp: $742.98kMs. Anna Trask M.A. (Age 65)Exec. VP & Chief People Officer Comp: $481.23kMr. John J. Lee (Age 55)Exec. VP & Chief Devel. Officer Comp: $596.15kMr. M. Charles LibermanCo-Founder & Member of Scientific Advisory BoardDr. Gabriel CorfasCo-Founder & Member of Scientific Advisory BoardDr. Ulrich MüllerCo-Founder & Member of Scientific Advisory BoardDr. Albert S. B. Edge (Age 68)Co-Founder & Member of Scientific Advisory Board Mr. James B. Murphy (Age 66)Interim CFO, Principal Financial Officer & Principal Accounting Officer Ms. Elaine Cope M.B.A.VP of OperationsMr. Geoff HorwitzVP of Corp. Devel. & Head of Bus. Devel.More ExecutivesKey CompetitorsKinnate BiopharmaNASDAQ:KNTENGM BiopharmaceuticalsNASDAQ:NGMProQR TherapeuticsNASDAQ:PRQRAssembly BiosciencesNASDAQ:ASMBvTv TherapeuticsNASDAQ:VTVTView All Competitors DBTX Stock Analysis - Frequently Asked Questions Should I buy or sell Decibel Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Decibel Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DBTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DBTX, but not buy additional shares or sell existing shares. View DBTX analyst ratings or view top-rated stocks. What is Decibel Therapeutics' stock price target for 2024? 2 brokerages have issued twelve-month price objectives for Decibel Therapeutics' stock. Their DBTX share price targets range from $5.25 to $5.25. On average, they anticipate the company's stock price to reach $5.25 in the next year. This suggests a possible upside of 6.9% from the stock's current price. View analysts price targets for DBTX or view top-rated stocks among Wall Street analysts. How were Decibel Therapeutics' earnings last quarter? Decibel Therapeutics, Inc. (NASDAQ:DBTX) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by $0.23. When did Decibel Therapeutics IPO? Decibel Therapeutics (DBTX) raised $100 million in an initial public offering on Friday, February 12th 2021. The company issued 5,900,000 shares at $16.00-$18.00 per share. Citigroup, BMO Capital Markets, SVB Leerink and Barclays acted as the underwriters for the IPO. This page (NASDAQ:DBTX) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceOptions trading has suddenly become more reliable.Eagle PublishingHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Decibel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.